Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Pfizer, Inc PFE with a price target of $33.Shibutani recalled that Pfizer had reported negative results from a Phase 3 study for a first-generation asset in March 2022, where the primary endpoint was unmet.Also Read: Elon Musk’s xAI To Expand With New Cha ...